Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Over the last 12 months, insiders at Verastem, Inc. have bought $0 and sold $282,940 worth of Verastem, Inc. stock.
On average, over the past 5 years, insiders at Verastem, Inc. have bought $108,500 and sold $1.46M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $108,500 was made by BARBERICH TIMOTHY J (director) on 2020‑12‑04.
2024-06-24 | Sale | Calkins Daniel | Chief Financial Officer | 28 0.0001% | $3.15 | $88 | -5.16% | |
2024-06-20 | Sale | Paterson Dan | President and CEO | 183 0.0007% | $3.21 | $587 | -4.62% | |
2024-06-20 | Sale | Stuglik Brian M | director | 335 0.0012% | $3.21 | $1,075 | -4.62% | |
2024-06-20 | Sale | Calkins Daniel | Chief Financial Officer | 67 0.0002% | $3.16 | $212 | -4.62% | |
2024-06-20 | Sale | Gagnon Robert E. | director | 131 0.0005% | $3.21 | $421 | -4.62% | |
2024-06-17 | Sale | Stuglik Brian M | director | 593 0.0024% | $3.49 | $2,070 | -8.93% | |
2024-06-17 | Sale | Paterson Dan | President and CEO | 244 0.001% | $3.49 | $852 | -8.93% | |
2024-06-17 | Sale | Gagnon Robert E. | director | 283 0.0011% | $3.49 | $988 | -8.93% | |
2024-04-05 | Sale | Calkins Daniel | Chief Financial Officer | 6 <0.0001% | $10.87 | $65 | -13.99% | |
2024-03-25 | Sale | Calkins Daniel | Chief Financial Officer | 25 0.0001% | $12.02 | $301 | -10.54% | |
2024-03-20 | Sale | Calkins Daniel | Chief Financial Officer | 55 0.0002% | $11.07 | $609 | -7.72% | |
2024-03-19 | Sale | Stuglik Brian M | director | 273 0.001% | $10.38 | $2,834 | -3.45% | |
2024-03-19 | Sale | Paterson Dan | President and CEO | 182 0.0007% | $10.38 | $1,889 | -3.45% | |
2024-03-19 | Sale | Gagnon Robert E. | director | 130 0.0005% | $10.38 | $1,349 | -3.45% | |
2024-03-18 | Sale | Stuglik Brian M | director | 537 0.0021% | $10.71 | $5,751 | +2.87% | |
2024-03-18 | Sale | Paterson Dan | President and CEO | 244 0.001% | $10.71 | $2,613 | +2.87% | |
2024-03-18 | Sale | Gagnon Robert E. | director | 283 0.0011% | $10.71 | $3,031 | +2.87% | |
2024-02-06 | Sale | Gagnon Robert E. | director | 9,204 0.0431% | $13.70 | $126,095 | -18.69% | |
2024-01-12 | Sale | Gagnon Robert E. | director | 9,204 0.0364% | $10.95 | $100,784 | +4.07% | |
2024-01-05 | Sale | Calkins Daniel | Chief Financial Officer | 6 <0.0001% | $8.50 | $51 | +33.41% |
Stuglik Brian M | director | 97045 0.358% | $3.07 | 1 | 22 | <0.0001% |
Paterson Dan | President and CEO | 236063 0.344% | $3.07 | 5 | 19 | <0.0001% |
Gagnon Robert E. | director | 35310 0.11% | $3.07 | 0 | 21 | |
Calkins Daniel | Chief Financial Officer | 47290 0.0341% | $3.07 | 0 | 17 | |
RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 16142051 63.8831% | $3.07 | 0 | 2 | |
CHP III LP | 10 percent owner | 2329121 9.2176% | $3.07 | 7 | 0 | +26.77% |
CLARKE JOHN K | director | 2329121 9.2176% | $3.07 | 7 | 0 | +26.77% |
MPM BIOVENTURES V LLC | 2033333 8.047% | $3.07 | 1 | 0 | ||
GADICKE ANSBERT | director | 2029593 8.0322% | $3.07 | 1 | 0 | |
Westphal Christoph H | Executive Chairman | 1230769 4.8708% | $3.07 | 12 | 0 | +22.02% |
ALDRICH RICHARD | director | 408142 1.6152% | $3.07 | 21 | 0 | <0.0001% |
Forrester Robert | President and CEO | 221234 0.8755% | $3.07 | 7 | 0 | <0.0001% |
BARBERICH TIMOTHY J | director | 218000 0.8627% | $3.07 | 7 | 0 | <0.0001% |
Bessemer Venture Partners VII L.P. | 100000 0.3958% | $3.07 | 1 | 0 | ||
Pachter Jonathan | VP, Head of Research | 66955 0.265% | $3.07 | 1 | 0 | +19.12% |
TERMEER HENRI A | director | 32179 0.1274% | $3.07 | 3 | 0 | +26.99% |
Phanstiel S. Louise | director | 26500 0.1049% | $3.07 | 4 | 0 | +28.84% |
Lobacki Joseph M | Executive VP & CCO | 10700 0.0423% | $3.07 | 2 | 0 | <0.0001% |
Kauffman Michael | director | 4000 0.0158% | $3.07 | 2 | 2 | <0.0001% |
Bloom Steven H. | Chief Strategy Officer | 3500 0.0139% | $3.07 | 1 | 0 | <0.0001% |
FRIEDMAN PAUL A | director | 3000 0.0119% | $3.07 | 1 | 0 | |
GREEN JOHN B | Chief Financial Officer | 2500 0.0099% | $3.07 | 4 | 0 | +19.12% |
SHERWIN STEPHEN A | director | 2500 0.0099% | $3.07 | 1 | 0 | |
Lawton Alison Frances | director | 2500 0.0099% | $3.07 | 1 | 0 | |
Singh Monica | General Counsel | 2000 0.0079% | $3.07 | 2 | 0 | |
Rowinsky Eric K | director | 2000 0.0079% | $3.07 | 1 | 0 | |
Horobin Joanna | Chief Medical Officer | 750 0.003% | $3.07 | 1 | 0 | |
Kraus Stephen | director | 0 0% | $3.07 | 1 | 0 |
Viking Global Investors | $28.98M | 9.7 | 2.46M | 0% | +$0 | 0.01 | |
Bvf Inc Il | $19.89M | 6.65 | 1.69M | 0% | +$0 | 0.15 | |
Soleus Capital Management, L.P. | $18.18M | 6.08 | 1.54M | +8.07% | +$1.36M | 0.17 | |
Deerfield Management | $18.15M | 6.08 | 1.54M | 0% | +$0 | 0.35 | |
Vivo Capital | $18.15M | 6.08 | 1.54M | 0% | +$0 | 1.6 | |
OrbiMed | $18.04M | 6.04 | 1.53M | 0% | +$0 | 0.37 | |
Adage Capital Partners Gp L L C | $15.93M | 5.33 | 1.35M | +3.85% | +$590,000.00 | 0.03 | |
The Vanguard Group | $13.7M | 4.58 | 1.16M | +0.93% | +$126,000.40 | <0.0001 | |
Millennium Management LLC | $7.39M | 2.47 | 625,942 | +653.11% | +$6.41M | 0.01 | |
Tang Capital Management, LLC | $6.39M | 2.14 | 541,514 | -26.97% | -$2.36M | 0.03 | |
BlackRock | $3.65M | 1.22 | 309,666 | -5.16% | -$198,782.81 | <0.0001 | |
Geode Capital Management | $2.94M | 0.98 | 248,952 | +7.25% | +$198,571.82 | <0.0001 | |
Susquehanna International Group | $2.75M | 0.92 | 233,283 | +43.73% | +$837,457.68 | <0.01 | |
Opaleye Management Inc | $2.49M | 0.84 | 211,400 | 0% | +$0 | 0.39 | |
ACUTA CAPITAL PARTNERS LLC | $2.44M | 0.82 | 207,095 | -10.83% | -$296,817.20 | 1.59 | |
Goldman Sachs | $2.05M | 0.69 | 173,736 | +696.99% | +$1.79M | <0.0001 | |
Jefferies Financial Group | $1.54M | 0.51 | 130,141 | -18.43% | -$346,920.04 | 0.03 | |
State Street | $1.03M | 0.35 | 87,487 | +4.67% | +$46,020.02 | <0.0001 | |
Qube Research & Technologies | $951,387.00 | 0.32 | 80,626 | +3,306.25% | +$923,456.39 | <0.01 | |
Citigroup | $911,196.00 | 0.31 | 77,220 | +4.48% | +$39,081.60 | <0.01 | |
Sectoral Asset Management | $875,560.00 | 0.29 | 74,200 | -63.51% | -$1.52M | 0.36 | |
Marshall Wace | $852,726.00 | 0.29 | 72,265 | New | +$852,726.00 | <0.01 | |
Hrt Financial Llc | $769,000.00 | 0.26 | 65,206 | New | +$769,000.00 | 0.01 | |
Morgan Stanley | $641,648.00 | 0.22 | 54,377 | -62.13% | -$1.05M | <0.0001 | |
Royal Bank of Canada | $630,000.00 | 0.21 | 53,383 | -2.34% | -$15,082.33 | <0.0001 | |
Ubs Oconnor Llc | $545,538.00 | 0.18 | 46,232 | -25.2% | -$183,737.93 | 0.05 | |
Northern Trust | $530,103.00 | 0.18 | 44,924 | 0% | +$0 | <0.0001 | |
Dimensional Fund Advisors | $515,105.00 | 0.17 | 43,653 | +10.73% | +$49,913.96 | <0.0001 | |
Citadel Advisors LLC | $469,734.00 | 0.16 | 39,808 | -93.09% | -$6.33M | <0.0001 | |
Marathon Trading Investment Management Llc | $397,660.00 | 0.13 | 33,700 | New | +$397,660.00 | 0.16 | |
JPMorgan Chase | $374,331.00 | 0.13 | 31,723 | +9,202.93% | +$370,307.20 | <0.0001 | |
Barclays | $367,000.00 | 0.12 | 31,061 | +2,827.52% | +$354,463.80 | <0.0001 | |
Balyasny Asset Management Llc | $359,853.00 | 0.12 | 30,496 | New | +$359,853.00 | <0.01 | |
Newedge Wealth Llc | $268,169.00 | 0.1 | 25,885 | 0% | +$0 | 0.01 | |
Cornercap Investment Counsel Inc | $298,233.00 | 0.1 | 25,274 | 0% | +$0 | 0.05 | |
Point72 Asia Singapore Pte Ltd | $294,764.00 | 0.1 | 24,980 | New | +$294,764.00 | 0.03 | |
Renaissance Technologies | $296,000.00 | 0.1 | 25,065 | -20.09% | -$74,398.56 | <0.0001 | |
Cibc World Markets Corp | $295,000.00 | 0.1 | 25,000 | New | +$295,000.00 | <0.01 | |
Brevan Howard Capital Management Lp | $285,127.00 | 0.1 | 24,102 | New | +$285,127.00 | 0.02 | |
Y Intercept Hong Kong Ltd | $228,849.00 | 0.08 | 19,394 | New | +$228,849.00 | 0.02 | |
Bank of America | $222,123.00 | 0.07 | 18,824 | -2.54% | -$5,793.80 | <0.0001 | |
Stifel | $204,167.00 | 0.07 | 17,303 | -1.52% | -$3,150.47 | <0.0001 | |
Cubist Systematic Strategies | $185,744.00 | 0.06 | 15,741 | New | +$185,744.00 | <0.01 | |
ExodusPoint Capital Management, LP | $174,000.00 | 0.06 | 14,752 | -71.29% | -$432,015.86 | <0.01 | |
American Century Investments | $167,902.00 | 0.06 | 14,229 | New | +$167,902.00 | <0.0001 | |
Aries Wealth Management | $154,356.00 | 0.05 | 13,081 | 0% | +$0 | 0.05 | |
Bank of Montreal | $158,400.00 | 0.05 | 13,200 | New | +$158,400.00 | <0.0001 | |
Two Sigma | $142,568.00 | 0.05 | 12,082 | -46.57% | -$124,254.35 | <0.0001 | |
Jane Street Capital | $133,293.00 | 0.05 | 11,296 | New | +$133,293.00 | <0.0001 | |
Charles Schwab | $131,676.00 | 0.04 | 11,159 | New | +$131,676.00 | <0.0001 |